Patents by Inventor Jih-Hwa Guh
Jih-Hwa Guh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10544178Abstract: A compound of formula (I) includes any forms of tautomer or stereoisomer thereof, wherein the formula (I) is presented as: wherein the definitions of X, R1, and R2 are as specified in the specification hereof. The preparing method and the usage in cancer treatment of such compound are also provided by the present invention.Type: GrantFiled: February 6, 2018Date of Patent: January 28, 2020Assignee: National Changhua University of EducationInventors: Jui-Hsien Huang, Chi-Meng Hsiao, Jih-Hwa Guh
-
Publication number: 20190241592Abstract: A compound of formula (I) includes any forms of tautomer or stereoisomer thereof, wherein the formula (I) is presented as: wherein the definitions of X, R1, and R2 are as specified in the specification hereof. The preparing method and the usage in cancer treatment of such compound are also provided by the present invention.Type: ApplicationFiled: February 6, 2018Publication date: August 8, 2019Inventors: JUI-HSIEN HUANG, CHI-MENG HSIAO, JIH-HWA GUH
-
Patent number: 8710062Abstract: This invention relates to piperazinedione compounds shown in the specification. These compounds are tyrosine kinase inhibitors and can be used to treat cancer.Type: GrantFiled: February 24, 2012Date of Patent: April 29, 2014Assignee: Taipei Medical UniversityInventors: Hui-po Wang, Che-Ming Teng, Chun-Li Wang, Jih-hwa Guh, Shiow-Lin Pan, Yuan-Yi Wang, Jang-Feng Lian
-
Patent number: 8501957Abstract: Benzimidazole compounds of formula (I): wherein R1, R2, R3, R4, R5, X, Y, Z1, and Z2 are defined herein. Also disclosed is a method for treating cancer with benzimidazole compounds.Type: GrantFiled: December 10, 2009Date of Patent: August 6, 2013Assignee: China Medical UniversityInventors: Chih-Shiang Chang, Jih-Hwa Guh, Che-Ming Teng, Shiow-Lin Pan, Wei-Ling Chang, Ju-Fang Liu, Kai-Wei Chang, Sheng-Chu Kuo
-
Patent number: 8383656Abstract: A method of inhibiting glycolysis in a subject by administering a pharmaceutical composition including a thiazolidinedione derivative to the subject is described. The thiazolidinedione derivatives are effective energy restriction mimetic agents, and can therefore be used to treat or prevent cancer in a subject, treat metabolic disorder, or increase the longevity of a subject. Various thiazolidinedione derivatives are also suitable for activating adenosine phosphate-activated protein kinase or inhibiting IL-6 expression.Type: GrantFiled: October 11, 2010Date of Patent: February 26, 2013Assignee: The Ohio State University Research FoundationInventors: Ching-Shih Chen, Jih-Hwa Guh
-
Publication number: 20120232088Abstract: This invention relates to piperazinedione compounds shown in the specification. These compounds are tyrosine kinase inhibitors and can be used to treat cancer.Type: ApplicationFiled: February 24, 2012Publication date: September 13, 2012Applicants: National Taiwan University, Taipei Medical UniversityInventors: Hui-Po Wang, Che-Ming Teng, Chun-Li Wang, Jih-hwa Guh, Shiow-Lin Pan, Yuan-Yi Wang, Jang-Feng Lian
-
Publication number: 20110086895Abstract: A method of inhibiting glycolysis in a subject by administering a pharmaceutical composition including a thiazolidinedione derivative to the subject is described. The thiazolidinedione derivatives are effective energy restriction mimetic agents, and can therefore be used to treat or prevent cancer in a subject, treat metabolic disorder, or increase the longevity of a subject. Various thiazolidinedione derivatives are also suitable for activating adenosine phosphate-activated protein kinase or inhibiting IL-6 expression.Type: ApplicationFiled: October 11, 2010Publication date: April 14, 2011Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Ching-Shih Chen, Jih-Hwa Guh
-
Publication number: 20100179147Abstract: Benzimidazole compounds of formula (I): wherein R1, R2, R3, R4, R5, X, Y, Z1, and Z2 are defined herein. Also disclosed is a method for treating cancer with benzimidazole compounds.Type: ApplicationFiled: December 10, 2009Publication date: July 15, 2010Inventors: Chih-Shiang Chang, Jih-Hwa Guh, Che-Ming Teng, Shiow-Lin Pan, Wei-Ling Chang, Ju-Fang Liu, Kai-Wei Chang, Sheng-Chu Kuo
-
Patent number: 7754751Abstract: A method for preferentially inhibiting release of pro-inflammatory cytokines over release of anti-inflammatory cytokines using a fused pyrazolyl compound of formula (I): A is R or in which R is H, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl; each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R1, R2, R3, R4, R5, and R6, independently, is R?, nitro, halogen, —C(O)—OR?, —C(O)—SR?, —C(O)—NR?R?, —(CH2)mOR?, —(CH2)mSR?, —(CH2)mNR?R?, —(CH2)mCN, —(CH2)mC(O)—OR?, —(CH2)mC(O)H, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are —O(CH2)nO—, in which each of R? and R?, independently, is H, alkyl, cyclyl, aryl, heteroaryl, heterocyclyl; and m is 0, 1, 2, 3, 4, 5, or 6; and n is 1, 2, or 3. This invention also covers a method of inhibiting activity of NF-?B with such a compound.Type: GrantFiled: March 15, 2005Date of Patent: July 13, 2010Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Che-Ming Teng, Jih-Hwa Guh, Shiow-Lin Pan, Sheng-Chu Kuo, Fang-Yu Lee
-
Patent number: 7378532Abstract: A fused pyrazolyl compound of the following formula: wherein A, Ar1, Ar2, R1, R2, R3, and R4, are as defined herein. Also disclosed is a pharmaceutical composition containing an effective amount of the above-described fused pyrazolyl compound.Type: GrantFiled: November 29, 2004Date of Patent: May 27, 2008Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Sheng-Chu Kuo, Fang-Yu Lee, Che-Ming Teng, Li-Jiau Huang, Li-Chen Chou, Jih-Hwa Guh, Shiow-Lin Pan
-
Patent number: 7288545Abstract: This invention relates to a method for treating an angiogenesis-related disease. The method includes administering to a subject in need thereof an effective amount of a piperazinedione compound having the formula: In the above formula, each of and , independently, is a single bond or a double bond; A is H or CH(RaRb) when is a single bond, or C(RaRb) when is a double bond; Z is CH(RcRd) when is a single bond, or C(RcRd) when is a double bond; each of R1 and R2, independently, is H, C(O)Re, C(O)ORe, C(O)NReRf, or SO2Re; and each of Ra, Rb, Rc, Rd, Re, and Rf, independently, is H, C1-C6 alkyl, aryl, heteroaryl, C3-C8 cycloalkyl, or C3-C8 heterocycloalkyl; or Ra and Rb taken together are C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, aryl, or heteroaryl; or R1 and Ra or R1 and Rb taken together are C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, aryl, or heteroaryl; provided that one of Rc and Rd is aryl or heteroaryl.Type: GrantFiled: October 20, 2003Date of Patent: October 30, 2007Assignee: AngioRx CorporationInventors: Che-Ming Teng, Hui-Po Wang, Eric I. C. Li, On Lee, Jih-Hwa Guh, Huei-Ting Chen, Ya-Bing Fan, Ya-Lan Chen
-
Publication number: 20070149554Abstract: A method for treating cancer, which includes administrating to a subject in need thereof an effective amount of a chemotherapeutic agent and an effective amount of a compound of the formula: in which, A is H or each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR?, (CH2)mOR, (CH2)mSR, (CH2)mNRR?, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH?NOR, (CH2)mC(O)N(OR)R?, N(OR)R?, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R?, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.Type: ApplicationFiled: December 21, 2006Publication date: June 28, 2007Applicant: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Sheng-Chu Kuo, Che-Ming Teng, Fang-Yu Lee, Shiow-Lin Pan, Jih-Hwa Guh
-
Publication number: 20070142449Abstract: A method for treating an angiogenesis-related disorder or cancer. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: Each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR?, (CH2)mOR, (CH2)mSR, (CH2)mNRR?, (CH2)mCN, (CH2)mC)O)OR, (CH2)mCHO, (CH2)mCH?NOR, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R?, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.Type: ApplicationFiled: January 3, 2007Publication date: June 21, 2007Applicant: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Che-Ming Teng, Sheng-Chu Kuo, Fang-Yu Lee, Shiow-Lin Pan, Jih-Hwa Guh
-
Patent number: 7166293Abstract: A method for treating an angiogenesis-related disorder. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: Each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR?, (CH2)mOR, (CH2)mSR, (CH2)mNRR?, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH?NOR, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R?, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.Type: GrantFiled: May 16, 2002Date of Patent: January 23, 2007Assignee: Carlsbad Technology, Inc.Inventors: Che-Ming Teng, Sheng-Chu Kuo, Fang Yu Lee, Shiow-Lin Pan, Jih-Hwa Guh
-
Publication number: 20050215613Abstract: A method for preferentially inhibiting release of pro-inflammatory cytokines over release of anti-inflammatory cytokines using a fused pyrazolyl compound of formula (I): A is R or in which R is H, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl; each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R1, R2, R3, R4, R5, and R6, independently, is R?, nitro, halogen, —C(O)—OR?, —C(O)—SR?, —C(O)—NR?R?, —(CH2)mOR?, —(CH2)mSR?, —(CH2)mNR?R?, —(CH2)mCN, —(CH2)mC(O)—OR?, —(CH2)mC(O)H, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are —O(CH2)nO—, in which each of R? and R?, independently, is H, alkyl, cyclyl, aryl, heteroaryl, heterocyclyl; and m is 0, 1, 2, 3, 4, 5, or 6; and n is 1, 2, or 3. This invention also covers a method of inhibiting activity of NF-?B with such a compound.Type: ApplicationFiled: March 15, 2005Publication date: September 29, 2005Inventors: Che-Ming Teng, Jih-Hwa Guh, Shiow-Lin Pan, Sheng-Chu Kuo, Fang-Yu Lee
-
Publication number: 20050215612Abstract: A fused pyrazolyl compound of the following formula: wherein A, Ar1, Ar2, R1, R2, R3, and R4, are as defined herein. Also disclosed is a pharmaceutical composition containing an effective amount of the above-described fused pyrazolyl compound.Type: ApplicationFiled: November 29, 2004Publication date: September 29, 2005Inventors: Sheng-Chu Kuo, Fang-Yu Lee, Che-Ming Teng, Li-Jiau Huang, Li-Chen Chou, Jih-Hwa Guh, Shiow-Lin Pan
-
Publication number: 20050209252Abstract: This invention relates to a method for treating cancer including administrating to a subject in need thereof an effective amount of a compound of the formula: wherein, A is H or each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR?, (CH2)mOR, (CH2)mSR, (CH2)mNRR?, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH?NOR, (CH2)mC(O)N(OR)R?, N(OR)R?, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R?, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.Type: ApplicationFiled: May 18, 2005Publication date: September 22, 2005Inventors: Che-Ming Teng, Sheng-Chu Kuo, Fang-Yu Lee, Shiow-Lin Pan, Jih-Hwa Guh
-
Patent number: 6943186Abstract: The present invention features a method for treating sepsis. The method includes administrating to a subject in need thereof an effective amount of a fused pyrazolyl compound of formula (I): A is H, C1˜C6 alkyl, or in which n is 0, 1, 2, or 3; each of Ar1, Ar2, and Ar3, independently, is phenyl, pyridinyl, thienyl, furyl, or pyrrolyl; and each of R1, R2, R3, R4, R5, and R6, independently, is XYZ; or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)1-6O; in which X is a bond or C1˜C6 alkylene, Y is a bond, O, S, OC(O), OC(O)(CH2)1-6C(O)O, C(O)O, C(O)S, C(O)NH, C(O)NC1˜C6 alkyl, NH, or NC1˜C6 alkyl, and Z is H, halogen, CN, NO2, or C1˜C6 alkyl; and provided that one of R3 and R4 is not H.Type: GrantFiled: January 24, 2003Date of Patent: September 13, 2005Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Che-Ming Teng, Shiow-Lin Pan, Jih-Hwa Guh, Sheng-Chu Kuo, Fang-Yu Lee
-
Publication number: 20050187257Abstract: The present invention features a method for treating sepsis. The method includes administrating to a subject in need thereof an effective amount of a fused pyrazolyl compound of formula (I): A is H, C1˜C6 alkyl, or in which n is 0, 1, 2, or 3; each of Ar1, Ar2, and Ar3, independently, is phenyl, pyridinyl, thienyl, furyl, or pyrrolyl; and each of R1, R2, R3, R4, R5, and R6, independently, is XYZ; or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)1-6O; in which X is a bond or C1˜C6 alkylene, Y is a bond, O, S, OC(O), OC(O)(CH2)1-6C(O)O, C(O)O, C(O)S, C(O)NH, C(O)NC1˜C6 alkyl, NH, or NC1˜C6 alkyl, and Z is H, halogen, CN, NO2, or C1˜C6 alkyl; and provided that one of R3 and R4 is not H.Type: ApplicationFiled: March 28, 2005Publication date: August 25, 2005Inventors: Che-Ming Teng, Shiow-Lin Pan, Jih-Hwa Guh, Sheng-Chu Kuo, Fang-Yu Lee
-
Publication number: 20050119278Abstract: A method for inhibiting cell proliferation, cell migration, or tube formation induced by an angiogenic factor. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: wherein A is H or in which n is 0, 1, 2, or 3; each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR?, (CH2)mOR, (CH2)mSR, (CH2)mNRR?, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH?NOR, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R?, independently, is H, alkyl, aryl, heteroaryl, cyclyl, or heterocyclyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.Type: ApplicationFiled: August 30, 2004Publication date: June 2, 2005Inventors: Che-Ming Teng, Sheng-Chu Kuo, Fang-Yu Lee, Shiow-Lin Pan, Jih-Hwa Guh